Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its lead antibody product candidate is SRK-015, an inhibitor of the activation of myostatin, which is in Phase I clinical trials for the treatment of spinal muscular atrophy.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone857-259-3860
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$380,000.00
Profitability
Miscellaneous
Employees65
Next Earnings Date11/13/2019 (Estimated)
OptionableNot Optionable
Scholar Rock (NASDAQ:SRRK) Frequently Asked Questions
What is Scholar Rock's stock symbol?
Scholar Rock trades on the NASDAQ under the ticker symbol "SRRK."
How were Scholar Rock's earnings last quarter?
Scholar Rock Holding Corp (NASDAQ:SRRK) posted its quarterly earnings data on Wednesday, August, 14th. The company reported ($0.48) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.41) by $0.07. The company had revenue of $5.04 million for the quarter, compared to analyst estimates of $5.38 million. View Scholar Rock's Earnings History.
When is Scholar Rock's next earnings date?
What price target have analysts set for SRRK?
2 equities research analysts have issued twelve-month price targets for Scholar Rock's shares. Their predictions range from $27.00 to $27.00. On average, they expect Scholar Rock's share price to reach $27.00 in the next twelve months. This suggests a possible upside of 187.2% from the stock's current price. View Analyst Price Targets for Scholar Rock.
What is the consensus analysts' recommendation for Scholar Rock?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Scholar Rock in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Scholar Rock.
Has Scholar Rock been receiving favorable news coverage?
News stories about SRRK stock have been trending negative recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Scholar Rock earned a news impact score of -2.5 on InfoTrie's scale. They also assigned media coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View News Stories for Scholar Rock.
Who are some of Scholar Rock's key competitors?
Some companies that are related to Scholar Rock include Editas Medicine (EDIT), Alector (ALEC), Sangamo Therapeutics (SGMO), Fate Therapeutics (FATE), Aerie Pharmaceuticals (AERI), BAVARIAN NORDIC/S (BVNRY), SpringWorks Therapeutics (SWTX), Twist Bioscience (TWST), NanoString Technologies (NSTG), AVITA MED LTD/S (RCEL), Rubius Therapeutics (RUBY), Vericel (VCEL), Atara Biotherapeutics (ATRA), Osiris Therapeutics (OSIR) and Krystal Biotech (KRYS).
What other stocks do shareholders of Scholar Rock own?
Who are Scholar Rock's key executives?
Scholar Rock's management team includes the folowing people:
- Mr. Nagesh K. Mahanthappa Ph.D., Pres, CEO & Exec. Director (Age 54)
- Mr. Yung H. Chyung, Chief Medical Officer (Age 43)
- Ms. Rhonda M. Chicko, Chief Financial Officer (Age 53)
- Mr. Alan J. Buckler, Chief Scientific Officer (Age 59)
- Ms. Catherine Hu, Exec. Director of Investor Relations & Corp. Communications
When did Scholar Rock IPO?
(SRRK) raised $76 million in an initial public offering on Thursday, May 24th 2018. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Cowen and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
Who are Scholar Rock's major shareholders?
Scholar Rock's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Bowling Portfolio Management LLC (0.07%). Company insiders that own Scholar Rock stock include Amir Nashat and International SCA Artal. View Institutional Ownership Trends for Scholar Rock.
Which institutional investors are buying Scholar Rock stock?
SRRK stock was purchased by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC. Company insiders that have bought Scholar Rock stock in the last two years include Amir Nashat and International SCA Artal. View Insider Buying and Selling for Scholar Rock.
How do I buy shares of Scholar Rock?
Shares of SRRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Scholar Rock's stock price today?
One share of SRRK stock can currently be purchased for approximately $9.40.
How big of a company is Scholar Rock?
Scholar Rock has a market capitalization of $278.99 million and generates $380,000.00 in revenue each year. The company earns $-49,330,000.00 in net income (profit) each year or ($3.15) on an earnings per share basis. Scholar Rock employs 65 workers across the globe.View Additional Information About Scholar Rock.
What is Scholar Rock's official website?
How can I contact Scholar Rock?
Scholar Rock's mailing address is 620 MEMORIAL DRIVE 2ND FLOOR, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-259-3860 or via email at [email protected]
MarketBeat Community Rating for Scholar Rock (NASDAQ SRRK)
MarketBeat's community ratings are surveys of what our community members think about Scholar Rock and other stocks. Vote "Outperform" if you believe SRRK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SRRK will underperform the S&P 500 over the long term. You may vote once every thirty days.
